Published in J Gastroenterol Hepatol on June 01, 2010
Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol (2014) 1.10
Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol (2014) 1.04
Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab (2011) 1.01
Betaine supplement alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice via reducing methylation of peroxisomal proliferator-activated receptor alpha promoter. Lipids Health Dis (2013) 0.95
Antioxidant properties of proanthocyanidins attenuate carbon tetrachloride (CCl4)-induced steatosis and liver injury in rats via CYP2E1 regulation. J Med Food (2014) 0.89
Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications. Redox Biol (2014) 0.89
Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet (2013) 0.88
Combined treatment of mulberry leaf and fruit extract ameliorates obesity-related inflammation and oxidative stress in high fat diet-induced obese mice. J Med Food (2013) 0.88
The heme oxygenase system rescues hepatic deterioration in the condition of obesity co-morbid with type-2 diabetes. PLoS One (2013) 0.87
ATF4 deficiency protects hepatocytes from oxidative stress via inhibiting CYP2E1 expression. J Cell Mol Med (2013) 0.85
Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev (2014) 0.85
The effects of choline on hepatic lipid metabolism, mitochondrial function and antioxidative status in human hepatic C3A cells exposed to excessive energy substrates. Nutrients (2014) 0.83
Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev (2016) 0.80
Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. BMC Pharmacol Toxicol (2016) 0.79
Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway. J Gastroenterol (2012) 0.79
Can skin exposure to sunlight prevent liver inflammation? Nutrients (2015) 0.77
Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases. Curr Mol Pharmacol (2015) 0.77
Autophagy in the liver: cell's cannibalism and beyond. Arch Pharm Res (2016) 0.76
Antioxidant and anti hyperglycemic role of wine grape powder in rats fed with a high fructose diet. Biol Res (2015) 0.75
Molecular basis for a functional role of cytochrome P450 2E1 in non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2010) 0.75
Amomum cardamomum L. ethyl acetate fraction protects against carbon tetrachloride-induced liver injury via an antioxidant mechanism in rats. BMC Complement Altern Med (2016) 0.75
Effect of BI-1 on insulin resistance through regulation of CYP2E1. Sci Rep (2016) 0.75
Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep (2017) 0.75
Effect of melatonin versus vitamin D as antioxidant and Hepatoprotective agents in STZ-induced diabetic rats. J Diabetes Metab Disord (2017) 0.75
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med (2008) 3.19
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 3.01
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest (2015) 2.93
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res (2007) 2.61
PNPASE regulates RNA import into mitochondria. Cell (2010) 2.54
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology (2014) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
Emerging role of epigenetics in the actions of alcohol. Alcohol Clin Exp Res (2008) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Impaired autophagic flux mediates acinar cell vacuole formation and trypsinogen activation in rodent models of acute pancreatitis. J Clin Invest (2009) 2.06
Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage. Gastroenterology (2010) 2.00
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Involvement of novel autophosphorylation sites in ATM activation. EMBO J (2006) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut (2010) 1.83
Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ Res (2006) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun (2003) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
ATM signaling and genomic stability in response to DNA damage. Mutat Res (2005) 1.75
Steatohepatitis induced by intragastric overfeeding in mice. Hepatology (2005) 1.73
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Epidemiology of alcoholic liver disease. Semin Liver Dis (2004) 1.66
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Aprataxin, a novel protein that protects against genotoxic stress. Hum Mol Genet (2004) 1.60
Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage. J Cell Biol (2007) 1.59
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol (2012) 1.55
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasis. Mol Cell Biol (2006) 1.49
Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp Mol Pathol (2008) 1.48
Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol (2005) 1.45
A new function in translocation for the mitochondrial i-AAA protease Yme1: import of polynucleotide phosphorylase into the intermembrane space. Mol Cell Biol (2006) 1.44
Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors. Am Surg (2002) 1.43
Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem (2003) 1.42
Epigenetic mechanisms regulate Mallory Denk body formation in the livers of drug-primed mice. Exp Mol Pathol (2008) 1.41
Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM. J Biol Chem (2002) 1.41
Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol (2011) 1.39
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
Gene expression patterns of the liver in response to alcohol: in vivo and in vitro models compared. Exp Mol Pathol (2006) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology (2009) 1.32
CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol (2006) 1.31
SAMe prevents the up regulation of toll-like receptor signaling in Mallory-Denk body forming hepatocytes. Exp Mol Pathol (2010) 1.29
Betaine prevents Mallory-Denk body formation in drug-primed mice by epigenetic mechanisms. Exp Mol Pathol (2008) 1.27
Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology (2002) 1.27
Chronic ethanol feeding alters hepatocyte memory which is not altered by acute feeding. Alcohol Clin Exp Res (2009) 1.27
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol (2010) 1.27
Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A (2002) 1.26
The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. Gastroenterology (2002) 1.24
A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol (2005) 1.23
Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A (2002) 1.23
The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology (2009) 1.21
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol (2006) 1.20
Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. FASEB J (2004) 1.19
Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology (2010) 1.19
Islet cell tumor arising from a heterotopic pancreas in the duodenal wall with ulceration. Exp Mol Pathol (2004) 1.19
The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes. Exp Mol Pathol (2010) 1.18
Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol (2006) 1.18
S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res (2007) 1.17
A rat model reproducing key pathological responses of alcoholic chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol (2007) 1.17
HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer (2012) 1.17
Preneoplastic liver cell foci expansion induced by thioacetamide toxicity in drug-primed mice. Exp Mol Pathol (2006) 1.14
The unique simultaneous occurrence of granular cell tumor, gastrointestinal stromal tumor, and gastric adenocarcinoma. Arch Pathol Lab Med (2005) 1.14
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Microarray analysis of gene expression in the liver during the urinary ethanol cycle in rats fed ethanol intragastrically at a constant rate. Exp Mol Pathol (2005) 1.13
Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease. Exp Mol Pathol (2004) 1.13
Animal models of alcoholic liver disease--focus on the intragastric feeding model. Alcohol Res Health (2003) 1.12
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Mallory body forming cells express the preneoplastic hepatocyte phenotype. Exp Mol Pathol (2006) 1.12
Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol (2012) 1.12
Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS One (2009) 1.12
The p105/50 NF-kappaB pathway is essential for Mallory body formation. Exp Mol Pathol (2005) 1.11
Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp Mol Pathol (2007) 1.10
The role of laminin-integrin signaling in triggering MB formation. An in vivo and in vitro study. Exp Mol Pathol (2005) 1.10
The effect of ethanol-induced CYP2E1 on proteasome activity: the role of 4-hydroxynonenal. Exp Mol Pathol (2004) 1.09
SAMe prevents the induction of the immunoproteasome and preserves the 26S proteasome in the DDC-induced MDB mouse model. Exp Mol Pathol (2010) 1.09